These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1059 related items for PubMed ID: 23273235

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H.
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [Abstract] [Full Text] [Related]

  • 3. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ, Li Q, Yan R, Zhou Y, Tang XW, Deng X, Xie SY, Chen ZP.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr 06; 51(4):336-340. PubMed ID: 28395468
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 06; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M, Hafizi M, Moghni M, Kheiri S, Esteghamati A, Sarikhani S.
    East Afr J Public Health; 2011 Jun 06; 8(2):88-91. PubMed ID: 22066292
    [Abstract] [Full Text] [Related]

  • 6. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 7. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 01; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A, Mitra M, Joshi HA, Nayak US, Siddaiah P, Babu TR, Mahapatro S, Sanmukhani J, Gupta G, Mittal R, Glueck R.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1523-1530. PubMed ID: 28362563
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Waning antibody levels and avidity: implications for MMR vaccine-induced protection.
    Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I.
    J Infect Dis; 2012 Nov 15; 206(10):1542-8. PubMed ID: 22966129
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group.
    Vaccine; 2018 Sep 11; 36(38):5781-5788. PubMed ID: 30104117
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M, Palmu AA, Syrjänen RK, Lahdenkari M, Ruokokoski E, Davidkin I, Vaarala O, Melin M.
    J Infect Dis; 2016 Jun 15; 213(12):2005-13. PubMed ID: 26908733
    [Abstract] [Full Text] [Related]

  • 18. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec 15; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H.
    J Infect Dis; 2008 Apr 01; 197(7):950-6. PubMed ID: 18419470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.